PCM
MRNA icon

Penserra Capital Management’s Moderna MRNA Stock Holding History

Penserra Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1K Buy
24
+15
+167% +$776 ﹤0.01% 1087
2026
Q1 		$0 Buy
+9
New +$420 ﹤0.01% 1155
2025
Q4 		– Sell
-18,291
Closed -$472K – 1116
2025
Q3 		$472K Buy
+18,291
New +$510K 0.01% 586
2025
Q1 		– Sell
-857
Closed -$35K – 1132
2024
Q4 		$35K Buy
857
+827
+2,757% +$39.5K ﹤0.01% 974
2024
Q3 		$2K Hold
30
– – ﹤0.01% 1027
2024
Q2 		$4K Hold
30
– – ﹤0.01% 1085
2024
Q1 		$3K Sell
30
-1,510
-98% -$152K ﹤0.01% 1115
2023
Q4 		$152K Sell
1,540
-319
-17% -$26.8K ﹤0.01% 819
2023
Q3 		$191K Sell
1,859
-271
-13% -$30.2K ﹤0.01% 760
2023
Q2 		$258K Sell
2,130
-15,679
-88% -$2.09M 0.01% 710
2023
Q1 		$2.73M Buy
17,809
+17,787
+80,850% +$2.93M 0.06% 269
2022
Q4 		$3K Buy
+22
New +$3.6K ﹤0.01% 1032
2021
Q4 		– Sell
-23,197
Closed -$8.93M – 1478
2021
Q3 		$8.93M Buy
+23,197
New +$8.56M 0.19% 161

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Penserra Capital Management's MRNA Position: Q2 2026 in Review

Penserra Capital Management increased its Moderna (MRNA) stake by 167% in Q2 2026, buying an estimated $776 and bringing the position to 24 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #1087.

Penserra Capital Management first reported a position in MRNA in Q3 2021 and has held it in 13 quarters since. The position peaked at $8.93M in Q3 2021. 783 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Penserra Capital Management held 24 shares of Moderna worth $1K as of Q2 2026.
  • Penserra Capital Management bought 15 Moderna shares in Q2 2026, an estimated $776.
  • Moderna made up ﹤0.01% of Penserra Capital Management's portfolio in Q2 2026, its #1087 holding.
  • Penserra Capital Management first reported a position in Moderna in Q3 2021 and has held it in 13 quarters since.
  • Penserra Capital Management's Moderna position peaked at $8.93M in Q3 2021.
  • 783 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Penserra Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.